Remarkably, within 2 years of the introduction of ipilimumab and vemurafenib into the clinic, major new advances have been reported in both the immune checkpoint blockade and small-molecule kinase inhibition arenas.
Patrick A. Ott, MD, PhD
Advertisement
Articles by Patrick A. Ott, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Elucidating CAR T-Cell Candidacy for Diffuse Large B-Cell Lymphomas
2
ASCO Breakthrough 2026 Wrap-Up: Precision Oncology, AI, and Biomarkers Define the Future of Cancer Care
3
Epcoritamab/Lenalidomide Significantly Improves PFS in R/R DLBCL
4
29 A Demonstration of Opportunity Cost in Surgical Delays When Using Needle Localization Versus MOLLI Localization in Breast Surgery
5